Host factors mediating HIV-1 replication
- PMID: 21871504
- DOI: 10.1016/j.virusres.2011.08.001
Host factors mediating HIV-1 replication
Abstract
Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?Biochem J. 2017 Apr 26;474(10):1559-1577. doi: 10.1042/BCJ20160772. Biochem J. 2017. PMID: 28446620 Review.
-
Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention.Cells. 2019 Sep 27;8(10):1155. doi: 10.3390/cells8101155. Cells. 2019. PMID: 31569640 Free PMC article. Review.
-
Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.Pharmacotherapy. 2009 Mar;29(3):295-304. doi: 10.1592/phco.29.3.295. Pharmacotherapy. 2009. PMID: 19249948 Review.
-
Maraviroc: a new CCR5 antagonist.Expert Rev Anti Infect Ther. 2009 Feb;7(1):9-19. doi: 10.1586/14787210.7.1.9. Expert Rev Anti Infect Ther. 2009. PMID: 19622053 Review.
-
Host proteins involved in HIV infection: new therapeutic targets.Biochim Biophys Acta. 2010 Mar;1802(3):313-21. doi: 10.1016/j.bbadis.2009.12.003. Epub 2009 Dec 16. Biochim Biophys Acta. 2010. PMID: 20018238 Review.
Cited by
-
Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein.J Virol. 2015 Apr;89(7):3497-511. doi: 10.1128/JVI.03347-14. Epub 2015 Jan 7. J Virol. 2015. PMID: 25568209 Free PMC article.
-
Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods.Biophys Rev. 2022 Oct 11;14(5):1109-1140. doi: 10.1007/s12551-022-00999-7. eCollection 2022 Oct. Biophys Rev. 2022. PMID: 36249860 Free PMC article. Review.
-
Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection.Iran J Basic Med Sci. 2014 Jan;17(1):49-54. Iran J Basic Med Sci. 2014. PMID: 24592307 Free PMC article.
-
HSP70 binding protein 1 (HspBP1) suppresses HIV-1 replication by inhibiting NF-κB mediated activation of viral gene expression.Nucleic Acids Res. 2016 Feb 29;44(4):1613-29. doi: 10.1093/nar/gkv1151. Epub 2015 Nov 3. Nucleic Acids Res. 2016. PMID: 26538602 Free PMC article.
-
Mitochondrial changes associated with viral infectious diseases in the paediatric population.Rev Med Virol. 2021 Nov;31(6):e2232. doi: 10.1002/rmv.2232. Epub 2021 Mar 31. Rev Med Virol. 2021. PMID: 33792105 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials